Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY03009 Formulations in Healthy Volunteers
NCT04593511Phase 1Unknown
- Sponsor
- Luye Pharma Group
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rotigotine in Parkinson's disease (PD) (4 arms), sponsored by Luye Pharma Group. Primary endpoint: Frequency of adverse events at Day 161. Status: unknown.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04593511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593511.